Spyridoula Maraka
Concepts (249)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypothyroidism | 23 | 2025 | 57 | 9.020 |
Why?
| Thyroxine | 24 | 2024 | 48 | 6.560 |
Why?
| Pregnancy Complications | 14 | 2025 | 400 | 5.050 |
Why?
| Thyrotropin | 15 | 2024 | 49 | 2.320 |
Why?
| Thyroid Gland | 10 | 2025 | 78 | 1.900 |
Why?
| Thyroid Diseases | 6 | 2025 | 27 | 1.820 |
Why?
| Diabetes Mellitus, Type 2 | 8 | 2022 | 560 | 1.520 |
Why?
| Asymptomatic Diseases | 4 | 2021 | 38 | 1.520 |
Why?
| Thyroid Nodule | 9 | 2023 | 31 | 1.400 |
Why?
| Abortion, Spontaneous | 4 | 2021 | 21 | 1.360 |
Why?
| Thyroid Neoplasms | 9 | 2023 | 116 | 1.270 |
Why?
| Pregnancy | 19 | 2025 | 2680 | 1.240 |
Why?
| Pre-Eclampsia | 2 | 2022 | 59 | 1.230 |
Why?
| Thyroid Function Tests | 9 | 2025 | 27 | 1.220 |
Why?
| Humans | 82 | 2025 | 52483 | 1.040 |
Why?
| Hormone Replacement Therapy | 4 | 2024 | 21 | 1.020 |
Why?
| Tachycardia | 2 | 2015 | 28 | 0.970 |
Why?
| Osteoporosis | 4 | 2025 | 162 | 0.960 |
Why?
| Bone Density Conservation Agents | 2 | 2015 | 75 | 0.930 |
Why?
| Diphosphonates | 2 | 2015 | 92 | 0.920 |
Why?
| Multiple Endocrine Neoplasia Type 1 | 2 | 2022 | 5 | 0.900 |
Why?
| Diabetes, Gestational | 3 | 2025 | 53 | 0.890 |
Why?
| Female | 46 | 2025 | 28171 | 0.890 |
Why?
| Cardiovascular Diseases | 3 | 2022 | 490 | 0.860 |
Why?
| Graves Disease | 5 | 2024 | 19 | 0.840 |
Why?
| Adult | 32 | 2024 | 14161 | 0.790 |
Why?
| Hyperthyroidism | 1 | 2022 | 28 | 0.760 |
Why?
| Neuroendocrine Tumors | 1 | 2022 | 23 | 0.760 |
Why?
| Hypertension | 3 | 2022 | 565 | 0.760 |
Why?
| Hypertension, Pregnancy-Induced | 1 | 2022 | 19 | 0.750 |
Why?
| Insulin | 5 | 2022 | 479 | 0.740 |
Why?
| Transsexualism | 2 | 2017 | 9 | 0.710 |
Why?
| Gonadal Steroid Hormones | 2 | 2017 | 39 | 0.700 |
Why?
| Electronic Health Records | 1 | 2023 | 268 | 0.690 |
Why?
| Iodine | 1 | 2020 | 12 | 0.680 |
Why?
| Suicidal Ideation | 1 | 2021 | 109 | 0.680 |
Why?
| Aircraft | 1 | 2020 | 8 | 0.680 |
Why?
| Hypoglycemic Agents | 6 | 2022 | 211 | 0.670 |
Why?
| Health Knowledge, Attitudes, Practice | 3 | 2022 | 509 | 0.670 |
Why?
| Infant Mortality | 1 | 2020 | 61 | 0.660 |
Why?
| Robotics | 1 | 2020 | 43 | 0.650 |
Why?
| Pancreatic Neoplasms | 1 | 2022 | 216 | 0.630 |
Why?
| Thyroid Hormones | 3 | 2022 | 22 | 0.630 |
Why?
| Bone Density | 5 | 2025 | 399 | 0.630 |
Why?
| Malnutrition | 1 | 2020 | 90 | 0.620 |
Why?
| Triiodothyronine | 4 | 2022 | 28 | 0.600 |
Why?
| Premature Birth | 3 | 2021 | 153 | 0.590 |
Why?
| Antithyroid Agents | 4 | 2024 | 8 | 0.580 |
Why?
| Rural Health Services | 1 | 2020 | 170 | 0.570 |
Why?
| Pregnancy Outcome | 5 | 2022 | 250 | 0.550 |
Why?
| Endocrinology | 3 | 2022 | 11 | 0.510 |
Why?
| Autoimmunity | 3 | 2025 | 34 | 0.510 |
Why?
| Fetal Growth Retardation | 1 | 2016 | 40 | 0.500 |
Why?
| Treatment Outcome | 12 | 2022 | 5422 | 0.500 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2020 | 403 | 0.480 |
Why?
| Retrospective Studies | 17 | 2024 | 6607 | 0.450 |
Why?
| Middle Aged | 23 | 2025 | 13028 | 0.430 |
Why?
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2013 | 4 | 0.430 |
Why?
| Teratoma | 1 | 2013 | 24 | 0.420 |
Why?
| Adrenal Gland Neoplasms | 3 | 2017 | 49 | 0.400 |
Why?
| Blood Pressure Monitoring, Ambulatory | 1 | 2012 | 34 | 0.390 |
Why?
| Male | 26 | 2025 | 26761 | 0.390 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2015 | 221 | 0.380 |
Why?
| Blood Glucose | 4 | 2021 | 473 | 0.360 |
Why?
| Iodide Peroxidase | 4 | 2024 | 4 | 0.350 |
Why?
| Mammaplasty | 2 | 2021 | 43 | 0.340 |
Why?
| Prescription Drugs | 2 | 2021 | 41 | 0.340 |
Why?
| Ovarian Neoplasms | 1 | 2013 | 459 | 0.310 |
Why?
| Free Tissue Flaps | 2 | 2021 | 63 | 0.300 |
Why?
| Myocardial Infarction | 2 | 2022 | 412 | 0.280 |
Why?
| Risk Factors | 6 | 2025 | 3889 | 0.270 |
Why?
| Hyperparathyroidism, Primary | 2 | 2016 | 35 | 0.260 |
Why?
| Parathyroidectomy | 2 | 2016 | 46 | 0.260 |
Why?
| Young Adult | 7 | 2024 | 4329 | 0.250 |
Why?
| Inappropriate Prescribing | 2 | 2016 | 23 | 0.250 |
Why?
| Decision Making | 3 | 2021 | 282 | 0.250 |
Why?
| Thyroidectomy | 3 | 2024 | 61 | 0.240 |
Why?
| Risk Assessment | 3 | 2021 | 1327 | 0.240 |
Why?
| United States | 7 | 2024 | 5192 | 0.240 |
Why?
| Phosphorylcholine | 1 | 2025 | 20 | 0.230 |
Why?
| Immunoglobulin M | 1 | 2025 | 60 | 0.230 |
Why?
| Thyroiditis, Autoimmune | 1 | 2024 | 2 | 0.230 |
Why?
| Aged | 15 | 2025 | 10121 | 0.230 |
Why?
| Cross-Sectional Studies | 4 | 2025 | 1678 | 0.220 |
Why?
| Biopsy, Fine-Needle | 4 | 2018 | 107 | 0.210 |
Why?
| Adolescent | 6 | 2024 | 6739 | 0.210 |
Why?
| Peripheral Vascular Diseases | 1 | 2022 | 23 | 0.200 |
Why?
| Vasoactive Intestinal Peptide | 1 | 2022 | 20 | 0.190 |
Why?
| Prospective Studies | 3 | 2024 | 2481 | 0.190 |
Why?
| Chorionic Gonadotropin | 1 | 2021 | 19 | 0.180 |
Why?
| Abdominoplasty | 1 | 2021 | 2 | 0.180 |
Why?
| Abdominal Wall | 1 | 2021 | 13 | 0.180 |
Why?
| Negative-Pressure Wound Therapy | 1 | 2020 | 11 | 0.180 |
Why?
| Ultrasonography, Interventional | 3 | 2016 | 140 | 0.180 |
Why?
| Metformin | 1 | 2022 | 76 | 0.180 |
Why?
| Transforming Growth Factor beta | 1 | 2021 | 138 | 0.170 |
Why?
| Thyroid (USP) | 1 | 2020 | 1 | 0.170 |
Why?
| Electronic Prescribing | 1 | 2020 | 2 | 0.170 |
Why?
| Islands | 1 | 2020 | 3 | 0.170 |
Why?
| Ireland | 1 | 2020 | 14 | 0.170 |
Why?
| Diabetes Mellitus | 2 | 2022 | 316 | 0.170 |
Why?
| Pheochromocytoma | 2 | 2017 | 35 | 0.170 |
Why?
| Patient Safety | 1 | 2021 | 104 | 0.170 |
Why?
| Iodine Radioisotopes | 1 | 2020 | 34 | 0.170 |
Why?
| Specimen Handling | 1 | 2020 | 56 | 0.160 |
Why?
| Patients | 1 | 2020 | 51 | 0.160 |
Why?
| Patient Participation | 2 | 2021 | 69 | 0.160 |
Why?
| Perception | 1 | 2020 | 120 | 0.160 |
Why?
| Hypoglycemia | 1 | 2019 | 59 | 0.160 |
Why?
| Autoantibodies | 3 | 2025 | 121 | 0.150 |
Why?
| Multiple Endocrine Neoplasia Type 2a | 1 | 2017 | 5 | 0.140 |
Why?
| Patient Education as Topic | 1 | 2021 | 321 | 0.140 |
Why?
| Ischemia | 1 | 2018 | 150 | 0.140 |
Why?
| Lower Extremity | 1 | 2018 | 100 | 0.140 |
Why?
| Databases, Factual | 2 | 2020 | 706 | 0.140 |
Why?
| Proto-Oncogene Proteins c-ret | 1 | 2017 | 33 | 0.140 |
Why?
| Stroke | 1 | 2022 | 512 | 0.140 |
Why?
| Follow-Up Studies | 3 | 2017 | 2279 | 0.130 |
Why?
| Time Factors | 2 | 2021 | 2968 | 0.130 |
Why?
| Apgar Score | 1 | 2016 | 35 | 0.130 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2017 | 188 | 0.130 |
Why?
| Telemedicine | 1 | 2022 | 494 | 0.130 |
Why?
| Bronchial Neoplasms | 1 | 2015 | 5 | 0.130 |
Why?
| Mutation | 1 | 2022 | 1347 | 0.130 |
Why?
| Carcinoid Tumor | 1 | 2015 | 15 | 0.120 |
Why?
| Thymus Neoplasms | 1 | 2015 | 17 | 0.120 |
Why?
| Physical Examination | 1 | 2016 | 99 | 0.120 |
Why?
| Infant | 2 | 2024 | 3733 | 0.120 |
Why?
| Infant, Low Birth Weight | 1 | 2016 | 79 | 0.120 |
Why?
| Ultrasonography | 3 | 2022 | 430 | 0.120 |
Why?
| Pancreas, Artificial | 1 | 2015 | 1 | 0.120 |
Why?
| Sensitivity and Specificity | 4 | 2021 | 891 | 0.120 |
Why?
| Adipocytes | 1 | 2016 | 132 | 0.120 |
Why?
| Multivariate Analysis | 1 | 2017 | 591 | 0.120 |
Why?
| Computer Security | 1 | 2015 | 20 | 0.120 |
Why?
| Stress, Physiological | 1 | 2016 | 183 | 0.120 |
Why?
| Postoperative Complications | 2 | 2020 | 1068 | 0.120 |
Why?
| Cell Transformation, Neoplastic | 1 | 2016 | 184 | 0.120 |
Why?
| Arkansas | 1 | 2021 | 2028 | 0.120 |
Why?
| Tomography, X-Ray Computed | 2 | 2017 | 1165 | 0.120 |
Why?
| Intensive Care Units, Neonatal | 1 | 2016 | 135 | 0.110 |
Why?
| Anthropometry | 1 | 2015 | 101 | 0.110 |
Why?
| Postoperative Period | 1 | 2015 | 170 | 0.110 |
Why?
| Fractures, Bone | 1 | 2015 | 107 | 0.110 |
Why?
| Bariatric Surgery | 1 | 2015 | 43 | 0.110 |
Why?
| Biopsy | 1 | 2016 | 605 | 0.110 |
Why?
| Logistic Models | 1 | 2017 | 925 | 0.110 |
Why?
| Early Detection of Cancer | 1 | 2015 | 189 | 0.110 |
Why?
| Quality of Life | 4 | 2022 | 879 | 0.100 |
Why?
| Case-Control Studies | 1 | 2016 | 1201 | 0.100 |
Why?
| White Coat Hypertension | 1 | 2012 | 1 | 0.100 |
Why?
| Maternal Age | 2 | 2024 | 45 | 0.100 |
Why?
| Body Weight | 1 | 2015 | 523 | 0.100 |
Why?
| Time | 1 | 2012 | 28 | 0.100 |
Why?
| Cohort Studies | 3 | 2024 | 1542 | 0.100 |
Why?
| Circadian Rhythm | 1 | 2012 | 91 | 0.100 |
Why?
| Practice Guidelines as Topic | 1 | 2015 | 488 | 0.100 |
Why?
| Aged, 80 and over | 4 | 2022 | 3392 | 0.090 |
Why?
| Renal Insufficiency | 1 | 2012 | 113 | 0.090 |
Why?
| Risk | 1 | 2012 | 316 | 0.090 |
Why?
| Antihypertensive Agents | 1 | 2012 | 132 | 0.090 |
Why?
| Bone and Bones | 1 | 2015 | 494 | 0.090 |
Why?
| Glucose | 2 | 2022 | 355 | 0.080 |
Why?
| Body Mass Index | 2 | 2024 | 689 | 0.080 |
Why?
| Drug Utilization | 2 | 2021 | 78 | 0.080 |
Why?
| Image-Guided Biopsy | 2 | 2016 | 34 | 0.060 |
Why?
| Nomograms | 1 | 2024 | 7 | 0.060 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2025 | 25 | 0.060 |
Why?
| Infant, Newborn | 2 | 2022 | 2867 | 0.060 |
Why?
| Predictive Value of Tests | 2 | 2017 | 944 | 0.050 |
Why?
| Recurrence | 1 | 2024 | 672 | 0.050 |
Why?
| Policy | 1 | 2022 | 27 | 0.050 |
Why?
| Thyroglobulin | 1 | 2022 | 7 | 0.050 |
Why?
| Goals | 1 | 2022 | 43 | 0.050 |
Why?
| Immunization, Passive | 1 | 2022 | 29 | 0.050 |
Why?
| Odds Ratio | 1 | 2024 | 558 | 0.050 |
Why?
| Reference Values | 1 | 2022 | 313 | 0.050 |
Why?
| Counseling | 1 | 2023 | 136 | 0.050 |
Why?
| Androgens | 1 | 2022 | 70 | 0.050 |
Why?
| Insurance Claim Review | 1 | 2021 | 40 | 0.050 |
Why?
| Physician-Patient Relations | 1 | 2023 | 143 | 0.050 |
Why?
| Colombia | 1 | 2021 | 15 | 0.050 |
Why?
| Iron-Binding Proteins | 1 | 2021 | 2 | 0.050 |
Why?
| Evidence-Based Medicine | 1 | 2022 | 261 | 0.050 |
Why?
| Parity | 1 | 2021 | 52 | 0.040 |
Why?
| Decision Support Techniques | 1 | 2021 | 70 | 0.040 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2021 | 46 | 0.040 |
Why?
| Glucose Tolerance Test | 1 | 2021 | 60 | 0.040 |
Why?
| Autoantigens | 1 | 2021 | 53 | 0.040 |
Why?
| Ambulatory Care | 1 | 2022 | 239 | 0.040 |
Why?
| China | 1 | 2021 | 134 | 0.040 |
Why?
| Communication | 1 | 2023 | 257 | 0.040 |
Why?
| Medication Adherence | 1 | 2022 | 133 | 0.040 |
Why?
| Abdomen | 1 | 2020 | 75 | 0.040 |
Why?
| Linear Models | 1 | 2021 | 287 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2021 | 395 | 0.040 |
Why?
| Florida | 1 | 2020 | 67 | 0.040 |
Why?
| Educational Status | 1 | 2021 | 226 | 0.040 |
Why?
| Blood Pressure | 1 | 2022 | 537 | 0.040 |
Why?
| Documentation | 1 | 2019 | 33 | 0.040 |
Why?
| Medicare | 1 | 2021 | 274 | 0.040 |
Why?
| Immunosuppressive Agents | 1 | 2021 | 243 | 0.040 |
Why?
| Oxygen | 1 | 2022 | 336 | 0.040 |
Why?
| Disease Management | 1 | 2020 | 188 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2021 | 595 | 0.040 |
Why?
| Optical Imaging | 1 | 2018 | 26 | 0.040 |
Why?
| Tibial Fractures | 1 | 2018 | 33 | 0.040 |
Why?
| Femur Neck | 1 | 2017 | 7 | 0.040 |
Why?
| Social Media | 1 | 2020 | 117 | 0.040 |
Why?
| Incidence | 1 | 2020 | 1062 | 0.030 |
Why?
| Hospitalization | 1 | 2022 | 736 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 180 | 0.030 |
Why?
| Recurrent Laryngeal Nerve Injuries | 1 | 2016 | 6 | 0.030 |
Why?
| Osteomyelitis | 1 | 2018 | 125 | 0.030 |
Why?
| Hypocalcemia | 1 | 2016 | 13 | 0.030 |
Why?
| Lumbar Vertebrae | 1 | 2017 | 104 | 0.030 |
Why?
| Methimazole | 1 | 2016 | 1 | 0.030 |
Why?
| 3T3-L1 Cells | 1 | 2016 | 13 | 0.030 |
Why?
| Hypercalcemia | 1 | 2016 | 34 | 0.030 |
Why?
| Health Literacy | 1 | 2018 | 132 | 0.030 |
Why?
| Caloric Restriction | 1 | 2016 | 38 | 0.030 |
Why?
| Primary Health Care | 1 | 2019 | 376 | 0.030 |
Why?
| Health Care Surveys | 1 | 2016 | 177 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2016 | 100 | 0.030 |
Why?
| Endpoint Determination | 1 | 2015 | 25 | 0.030 |
Why?
| Observer Variation | 1 | 2016 | 134 | 0.030 |
Why?
| Uncertainty | 1 | 2015 | 44 | 0.030 |
Why?
| Diagnostic Errors | 1 | 2016 | 68 | 0.030 |
Why?
| Lipids | 1 | 2016 | 155 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2016 | 243 | 0.030 |
Why?
| Madagascar | 1 | 2015 | 3 | 0.030 |
Why?
| Child, Preschool | 1 | 2024 | 4076 | 0.030 |
Why?
| Metabolomics | 1 | 2016 | 150 | 0.030 |
Why?
| Diagnosis, Differential | 1 | 2018 | 1046 | 0.030 |
Why?
| Patient-Centered Care | 1 | 2016 | 141 | 0.030 |
Why?
| Insulin Resistance | 1 | 2016 | 275 | 0.030 |
Why?
| Proteomics | 1 | 2016 | 329 | 0.030 |
Why?
| Proteins | 1 | 2016 | 348 | 0.030 |
Why?
| Referral and Consultation | 1 | 2015 | 292 | 0.030 |
Why?
| Pilot Projects | 1 | 2015 | 721 | 0.030 |
Why?
| Cells, Cultured | 1 | 2016 | 1567 | 0.020 |
Why?
| MicroRNAs | 1 | 2016 | 387 | 0.020 |
Why?
| Registries | 1 | 2015 | 581 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2016 | 1884 | 0.020 |
Why?
| Prognosis | 1 | 2016 | 2099 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2015 | 1546 | 0.020 |
Why?
| Obesity | 1 | 2016 | 1162 | 0.020 |
Why?
| Mice | 1 | 2016 | 5949 | 0.020 |
Why?
| Animals | 1 | 2016 | 13505 | 0.010 |
Why?
|
|
Maraka's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|